| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Medicine, Section of Hematology/Oncology, The University of Chicago, Chicago, Illinois 60637 [M. E. D., R. B. M.], and Carcinogen-Modified Nucleic Acid Chemistry, Chemistry of Carcinogenesis Laboratory, ABL-Basic Research Program, National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, Maryland 21702 [R. C. M.]
We have previously shown that O6-benzylguanine can be used to deplete cells of the DNA repair protein O6-alkylguanine-DNA alkyltransferase and to enhance the sensitivity of human glioma (SF767) and colon tumor (HT29) cells to the cytotoxic effects of alkylnitrosoureas. In the present study, the combination of O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) was evaluated in vitro to determine the number of DNA interstrand cross-links formed and in vivo to compare the therapeutic index with that of BCNU alone. The number of DNA interstrand cross-links, as measured by alkaline elution, was increased in HT29 cells treated with 10 µM O6-benzylguanine for 2 h prior to BCNU exposure compared to cells treated with BCNU only. The number of single strand breaks was not increased by prior exposure to O6-benzylguanine. To evaluate the therapeutic index, HT29 and SF767 cells were grown as xenografts in nude mice and the tumor growth rate after treatment with BCNU alone was compared with the rate after treatment with O6-benzylguanine and BCNU. Treatment was administered i.p. when tumors reached 100–200 mm3. For animals bearing HT29 xenografts that were treated with 60 mg/kg O6-benzylguanine 1 h prior to 20 mg/kg BCNU, the average time for tumor volume to increase by 200% was 25 days, compared to 10 days for animals treated with 20 mg/kg BCNU alone. For animals bearing SF767 xenografts, the tumor growth of controls was not significantly different from that of animals treated with O6-benzylguanine alone or BCNU alone up to the maximally tolerated dose (50 mg/kg). For these 3 groups, the average time for tumors to reach 300 mm3 was 9–12 days. However, when animals were treated with 80 mg/kg O6-benzylguanine 1 h prior to receiving 20 mg/kg BCNU tumor size did not increase for at least 21 days. Our studies demonstrate that the therapeutic index of BCNU can be increased when given in combination with O6-benzylguanine.
1 This work was supported by NIH Grants CA-47228 (M. E. D.) and 5T32-DK-07134 (R. B. M.) and Contract N01-CO-74101 with ABL (R. C. M.). Equipment funds were provided by a gift from the Alcoa Foundation.
2 To whom requests for reprints should be addressed, at the University of Chicago, Department of Medicine, Section of Hematology/Oncology, 5841 S. Maryland Ave., Box MC2115, Chicago, IL 60637.
Received 9/20/91. Accepted 12/16/91.
This article has been cited by other articles:
|
|
 |
|
  T. Ueno, S. H. Ko, E. Grubbs, Y. Yoshimoto, C. Augustine, Z. Abdel-Wahab, T.-Y. Cheng, O. I. Abdel-Wahab, S. K. Pruitt, H. S. Friedman, et al. Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine. Mol. Cancer Ther., March 1, 2006; 5(3): 732 - 738. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Warren, A. A. Aikin, M. Libucha, B. C. Widemann, E. Fox, R. J. Packer, and F. M. Balis Phase I Study of O6-Benzylguanine and Temozolomide Administered Daily for 5 Days to Pediatric Patients With Solid Tumors J. Clin. Oncol., October 20, 2005; 23(30): 7646 - 7653. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. Kreklau, K. E. Pollok, B. J. Bailey, N. Liu, J. R. Hartwell, D. A. Williams, and L. C. Erickson Hematopoietic expression of O6-methylguanine DNA methyltransferase-P140K allows intensive treatment of human glioma xenografts with combination O6-benzylguanine and 1,3-bis-(2-chloroethyl)-1-nitrosourea Mol. Cancer Ther., December 1, 2003; 2(12): 1321 - 1329. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. S. Friedman, S. Keir, A. E. Pegg, P. J. Houghton, O. M. Colvin, R. C. Moschel, D. D. Bigner, and M. E. Dolan O6-Benzylguanine-mediated Enhancement of Chemotherapy Mol. Cancer Ther., September 1, 2002; 1(11): 943 - 948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Dolan, M. Posner, T. Karrison, J. Radosta, G. Steinberg, D. Bertucci, L. Vujasin, and M. J. Ratain Determination of the Optimal Modulatory Dose of O6-Benzylguanine in Patients with Surgically Resectable Tumors Clin. Cancer Res., August 1, 2002; 8(8): 2519 - 2523. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Liu, S. Schwartz, B. M. Davis, and S. L. Gerson Chemotherapy-induced O6-Benzylguanine-resistant Alkyltransferase Mutations in Mismatch-deficient Colon Cancer Cancer Res., June 1, 2002; 62(11): 3070 - 3076. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Quinn, J. Pluda, M. E. Dolan, S. Delaney, R. Kaplan, J. N. Rich, A. H. Friedman, D. A. Reardon, J. H. Sampson, O. M. Colvin, et al. Phase II Trial of Carmustine Plus O6-Benzylguanine for Patients With Nitrosourea-Resistant Recurrent or Progressive Malignant Glioma J. Clin. Oncol., May 1, 2002; 20(9): 2277 - 2283. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Dowlati, J. Haaga, S. C. Remick, T. P. Spiro, S. L. Gerson, L. Liu, S. J. Berger, N. A. Berger, and J. K. V. Willson Sequential Tumor Biopsies in Early Phase Clinical Trials of Anticancer Agents for Pharmacodynamic Evaluation Clin. Cancer Res., October 1, 2001; 7(10): 2971 - 2976. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Liu, T. P. Spiro, X. Qin, S. Majka, J. Haaga, J. Schupp, J. K. V. Willson, and S. L. Gerson Differential Degradation Rates of Inactivated Alkyltransferase in Blood Mononuclear Cells and Tumors of Patients after Treatment with O6-Benzylguanine Clin. Cancer Res., August 1, 2001; 7(8): 2318 - 2324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. L. Kreklau, N. Liu, Z. Li, K. Cornetta, and L. C. Erickson Comparison of Single- Versus Double-Bolus Treatments of O6-Benzylguanine for Depletion of O6-Methylguanine DNA Methyltransferase (MGMT) Activity in Vivo: Development of a Novel Fluorometric Oligonucleotide Assay for Measurement of Mgmt Activity J. Pharmacol. Exp. Ther., April 12, 2001; 297(2): 524 - 530. [Abstract] [Full Text]
|
|
|
|
|
|
Z.-P. Chen, Z.-M. Wang, C. A. Carter, M. C. Alley, G. Mohr, and L. C. Panasci Both Extraneuronal Monoamine Transporter and O6-Methylguanine-DNA Methyltransferase Expression Influence the Antitumor Efficacy of 2-Chloroethyl-3-sarcosinamide- 1-nitrosourea in Human Tumor Xenografts J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 712 - 715. [Abstract] [Full Text]
|
|
|
|
|
|
L. D. Rhines, P. Sampath, M. E. Dolan, B. M. Tyler, H. Brem, and J. Weingart O6-Benzylguanine Potentiates the Antitumor Effect of Locally Delivered Carmustine against an Intracranial Rat Glioma Cancer Res., November 1, 2000; 60(22): 6307 - 6310. [Abstract] [Full Text]
|
|
|
|
|
|
H. S. Friedman, J. Pluda, J. A. Quinn, R. B. Ewesuedo, L. Long, A. H. Friedman, I. Cokgor, O. M. Colvin, M. M. Haglund, D. M. Ashley, et al. Phase I Trial of Carmustine Plus O6-Benzylguanine for Patients With Recurrent or Progressive Malignant Glioma J. Clin. Oncol., October 20, 2000; 18(20): 3522 - 3528. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ragg, M. Xu-Welliver, J. Bailey, M. D’Souza, R. Cooper, S. Chandra, R. Seshadri, A. E. Pegg, and D. A. Williams Direct Reversal of DNA Damage by Mutant Methyltransferase Protein Protects Mice against Dose-intensified Chemotherapy and Leads to in Vivo Selection of Hematopoietic Stem Cells Cancer Res., September 1, 2000; 60(18): 5187 - 5195. [Abstract] [Full Text]
|
|
|
|
|
|
L. Long, S. L. Berg, S. K. Roy, C. L. McCully, H.-W. Song-Yoo, R. C. Moschel, F. M. Balis, and M. E. Dolan Plasma and Cerebrospinal Fluid Pharmacokinetics of O6-Benzylguanine and Analogues in Nonhuman Primates Clin. Cancer Res., September 1, 2000; 6(9): 3662 - 3669. [Abstract] [Full Text]
|
|
|
|
|
|
R. L. Schilsky, M. E. Dolan, D. Bertucci, R. B. Ewesuedo, N. J. Vogelzang, S. Mani, L. R. Wilson, and M. J. Ratain Phase I Clinical and Pharmacological Study of O6-Benzylguanine Followed by Carmustine in Patients with Advanced Cancer Clin. Cancer Res., August 1, 2000; 6(8): 3025 - 3031. [Abstract] [Full Text]
|
|
|
|
|
|
E. L. Kreklau, C. Kurpad, D. A. Williams, and L. C. Erickson Prolonged Inhibition of O6-Methylguanine DNA Methyltransferase in Human Tumor Cells by O6-Benzylguanine In Vitro and In Vivo J. Pharmacol. Exp. Ther., December 1, 1999; 291(3): 1269 - 1275. [Abstract] [Full Text]
|
|
|
|
|
|
Z.-P. Chen, J. Remack, T. P. Brent, G. Mohr, and L. C. Panasci Extraneuronal Monoamine Transporter Expression and DNA Repair Vis-a-Vis 2-Chloroethyl-3-sarcosinamide-1-nitrosourea Cytotoxicity in Human Tumor Cell Lines Clin. Cancer Res., December 1, 1999; 5(12): 4186 - 4190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Maze, C. Kurpad, A. E. Pegg, L. C. Erickson, and D. A. Williams Retroviral-Mediated Expression of the P140A, but not P140A/G156A, Mutant Form of O6-Methylguanine DNA Methyltransferase Protects Hematopoietic Cells against O6-Benzylguanine Sensitization to Chloroethylnitrosourea Treatment J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1467 - 1474. [Abstract] [Full Text]
|
|
|
|
|
|
T. P. Spiro, S. L. Gerson, L. Liu, S. Majka, J. Haaga, C. L. Hoppel, S. T. Ingalls, J. M. Pluda, and J. K. V. Willson O6-Benzylguanine: A Clinical Trial Establishing the Biochemical Modulatory Dose in Tumor Tissue for Alkyltransferase-directed DNA Repair Cancer Res., May 1, 1999; 59(10): 2402 - 2410. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Reese, B. M. Davis, L. Liu, and S. L. Gerson Simultaneous Protection of G156A Methylguanine DNA Methyltransferase Gene-transduced Hematopoietic Progenitors and Sensitization of Tumor Cells Using O6-Benzylguanine and Temozolomide Clin. Cancer Res., January 1, 1999; 5(1): 163 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Wu, K. E. Lohrbach, O. I. Olopade, D. M. Kokkinakis, H. S. Friedman, and M. E. Dolan Lack of Evidence for a Polymorphism at Codon 160 of Human O6-Alkylguanine-DNA Alkyltransferase Gene in Normal Tissue and Cancer Clin. Cancer Res., January 1, 1999; 5(1): 209 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Chinnasamy, J. A. Rafferty, I. Hickson, J. Ashby, H. Tinwell, G. P. Margison, T. M. Dexter, and L. J. Fairbairn O6-Benzylguanine Potentiates the In Vivo Toxicity and Clastogenicity of Temozolomide and BCNU in Mouse Bone Marrow Blood, March 1, 1997; 89(5): 1566 - 1573. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
